Mesa Laboratories (MLAB) CEO awarded 35,236 restricted stock units in Form 4/A
Mesa Laboratories' President and CEO, Siddhartha Kadia, was granted 35,236 restricted stock units (RSUs) as recorded in a Form 4/A filing. These RSUs, valued at $0.00 per unit as stock-based compensation, will vest in three equal annual installments, representing a right to receive one common stock share per RSU upon vesting. Following this award, Kadia directly holds 35,236 RSUs tied to common stock, according to the filing made on May 19, 2026, which amended an original filing from April 24, 2026.
Mesa Laboratories stock (US59064R1095): Precision tools for life sciences
Mesa Laboratories provides essential monitoring and quality control solutions for the healthcare and life sciences sectors, focusing on regulatory compliance in pharmaceuticals and biotech. The company's diverse portfolio includes biological indicators, data loggers, and genetic testing services, with a business model that generates recurring revenue from consumables and subscriptions. Mesa Laboratories is positioned for growth within the expanding life sciences tools market, making it noteworthy for US investors due to its alignment with the robust biopharma industry.
Mesa Laboratories Inc at JPMorgan Healthcare Conference Transcript
Mesa Laboratories Inc. participated in the 44th annual JPMorgan Healthcare Conference. The company was represented by CEO Gary Owens and CFO John Sakki. The conference presentation included a safe harbor statement from Mesa Labs.
Mesa Laboratories, Inc. Scheduled to Release Q4 and Fiscal Year 2026 Financial Results on May 27, 2026
Mesa Laboratories, Inc. announced it will release its Q4 and fiscal year 2026 financial results on May 27, 2026, at 6:00 A.M. Eastern Time. The company, a leader in life science tools and quality control solutions, aims to enhance product integrity and patient safety. The announcement is expected to foster transparency and could attract investor interest, despite the press release lacking specific financial data or immediate results.
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
Mesa Laboratories, Inc. (NASDAQ: MLAB) is scheduled to release its financial results for the fourth quarter and the full fiscal year ended March 31, 2026, on Wednesday, May 27, 2026, at approximately 6:00 A.M. ET. The company is a global leader in life science tools and quality control solutions for regulated industries. Investors can find more information about the company on its website.
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
Mesa Laboratories, Inc. (NASDAQ:MLAB) will release its financial results for the fourth quarter and the fiscal year ending March 31, 2026, on Wednesday, May 27, 2026, at approximately 6:00 A.M. Eastern Time. The company is a global leader in life science tools and critical quality control solutions for regulated industries.
Mesa Labs sets May 27 release for full-year and Q4 results
Mesa Laboratories (NASDAQ: MLAB) will release its fourth-quarter and full fiscal year 2026 financial results on Wednesday, May 27, 2026, at approximately 6:00 A.M. ET. The announcement confirms the company will issue a press release detailing results for the period ending March 31, 2026. Historically, similar earnings date announcements have led to only modest share price movements for MLAB, around +1.0%.
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
Mesa Laboratories, Inc. (NASDAQ:MLAB) will release its financial results for the fourth quarter and the full fiscal year ended March 31, 2026, on Wednesday, May 27, 2026, at approximately 6:00 A.M. Eastern Time. The company is a global leader in life science tools and quality control solutions for regulated industries.
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
Mesa Laboratories, Inc. (NASDAQ:MLAB) will disclose its financial results for the fourth quarter and the full fiscal year ending March 31, 2026, on Wednesday, May 27, 2026, at approximately 6:00 A.M. ET. The company specializes in life science tools and quality control solutions for regulated industries.
Mesa Laboratories Inc at JPMorgan Healthcare Conference Transcript
This article provides the transcript of Mesa Laboratories Inc.'s presentation at the JPMorgan Healthcare Conference on January 15, 2026. CEO Gary Owens and CFO John Sakki were introduced during the conference. The full transcript details their discussion at the event.
Mesa Laboratories (MLAB) CEO receives 34,807 RSU equity award
Mesa Laboratories (MLAB) CEO Siddhartha Kadia has been granted 34,807 Restricted Stock Units (RSUs) as part of his compensation package. These RSUs, which vest in three equal annual installments, align the CEO's long-term interests with the company's performance. This equity award is a standard form of executive compensation and is not considered a market purchase or sale of stock.
Mesa Labs (MLAB) CEO Kadia files Form 3 with no insider trades
Mesa Laboratories' President and CEO, Siddhartha Kadia, has filed a Form 3 insider report, which is an initial statement of beneficial ownership. The filing indicates he is an officer of the company but shows no reported purchases, sales, gifts, tax withholdings, or derivative transactions, meaning no insider trades or holdings are disclosed in this specific report. This Form 3 acts as an opening inventory sheet for his ownership at Mesa Labs, providing transparency without any immediate trading activity.
Mesa Laboratories names new CEO
This article announces that Mesa Laboratories has named a new CEO. No further details are available in the provided content.
Mesa Laboratories (NASDAQ:MLAB) Share Price Crosses Above 200-Day Moving Average - Should You Sell?
Mesa Laboratories (NASDAQ:MLAB) shares have crossed above their 200-day moving average, reaching $101.65, signaling a bullish technical trend. The company also reported strong quarterly earnings, beating analyst expectations. Despite this, analyst sentiment remains mixed with a "Reduce" rating and a target price below the current stock value, though insider buying activity has increased.
Long Path discloses 7.3% stake in Mesa Labs (NASDAQ: MLAB)
Long Path funds and affiliated managers have filed an amended Schedule 13G/A, reporting a 7.3% stake in Mesa Laboratories, Inc. (NASDAQ: MLAB). This passive investment accounts for 405,583 shares of common stock, based on 5,524,813 shares outstanding as of January 31, 2026. The filing indicates shared voting and dispositive power among the reporting entities.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is scheduled to be paid on June 15, 2026, to shareholders who are on record as of May 29, 2026. Mesa Labs specializes in life science tools and quality control solutions for regulated industries.
MLAB Technical Analysis & Stock Price Forecast
Mesa Laboratories Inc. (MLAB) currently shows a "Strong Buy" technical sentiment based on an aggregation of 15 technical signals, with 11 indicators flashing buy and 4 indicating sell. The stock is trading above its 60-day and 200-day moving averages, suggesting a potentially bullish long-term trend, though its Relative Strength Index (RSI) is in neutral territory. Key resistance is at $94.029 and strong support is at $78.499.
MLAB Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an in-depth financial analysis of Mesa Laboratories Inc (MLAB), detailing its revenue breakdown, profitability margins, and a comparison with competitors. MLAB's primary revenue source is Discrete Revenues- Consumables, contributing 55.0% of total sales, and it maintains strong gross and operating margins. The article benchmarks MLAB's financial performance against industry rivals VREX and ANGO, highlighting its competitive standing within the Medical Equipment, Supplies & Distribution sector.
Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2026
Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. This dividend will be payable on June 15, 2026, to shareholders who are of record at the close of business on May 29, 2026. The announcement was made on April 3, 2026.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend will be paid on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa Labs is a global leader in life science tools and quality control solutions for regulated industries.
Mesa Labs Declares Quarterly Dividend
Mesa Laboratories, Inc. has announced a regular quarterly dividend of $0.16 per share of common stock, payable on June 15, 2026, to shareholders of record by May 29, 2026. This dividend demonstrates Mesa's financial stability and commitment to returning value to shareholders, despite industry and economic challenges. The consistent payout reflects the company's strong cash flow and positive long-term outlook in the life sciences and medical technology sectors.
Mesa Labs Declares Quarterly Dividend
Mesa Laboratories, Inc. has declared a regular quarterly dividend of $0.16 per share, payable on June 15, 2026, to shareholders of record by May 29, 2026. This dividend highlights the company's financial stability and its ongoing commitment to providing value to its shareholders. The consistent payout reinforces Mesa Labs' strong business model and its ability to generate stable cash flows.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is scheduled to be paid on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa Labs specializes in life science tools and quality control solutions for various regulated industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is set to be paid on June 15, 2026, to shareholders of record as of May 29, 2026. The company is a global leader in life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa Labs specializes in life science tools and quality control solutions for regulated industries.
Mesa Laboratories Inc. (MLAB) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Mesa Laboratories Inc. (MLAB), showing its current price, intraday change, and percentage change. It also includes information on average price target (currently N/A due to zero analyst ratings in the last 3 months) and notes the absence of earnings information. The content is presented by StocksToTrade.com, emphasizing that it is for informational purposes only and not investment advice.
Mesa Laboratories (MLAB) CEO RSUs expire as 8,211 units forfeited
Mesa Laboratories President and CEO Gary M. Owens reported the expiration and forfeiture of 8,211 restricted stock units (RSUs). These RSUs, initially scheduled to vest on June 15, 2028, were deemed expired on March 31, 2026, and returned to the company. Following this transaction, Owens still holds 16,448 restricted stock units directly.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on June 15, 2026, to shareholders of record as of May 29, 2026. The company is a global leader in life science tools and quality control solutions for regulated industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ: MLAB) announced a regular quarterly dividend of $0.16 per share of common stock. The dividend is payable on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa is a global leader in life science tools and quality control solutions for regulated industries.
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record as of May 29, 2026. Mesa is a global leader in life science tools and quality control solutions for regulated industries.
Mesa Laboratories (NASDAQ:MLAB) Stock Price Passes Above 200-Day Moving Average - What's Next?
Mesa Laboratories (NASDAQ:MLAB) shares have moved above their 200-day moving average, signaling short-term bullish momentum, despite analysts maintaining a "Reduce" consensus rating with a $94 price target. The company recently exceeded earnings expectations and saw significant insider buying, while institutional investors also increased their holdings. However, MLAB's valuation shows a high P/E ratio of 138.22 and a modest dividend yield of 0.7%.
Mesa Labs sets June 15 payout for $0.16 quarterly dividend
Mesa Laboratories (NASDAQ: MLAB) has declared a regular quarterly dividend of $0.16 per share, payable on June 15, 2026, to shareholders of record as of May 29, 2026. The announcement, made on April 2, 2026, led to a 3.49% stock gain for MLAB on the day of publication. The company also included a standard forward-looking risk disclaimer in its press release.
Vanguard disaggregates holdings after realignment — Mesa Laboratories (MLAB)
Vanguard has filed an amended Schedule 13G/A, reporting 0 shares beneficially owned in Mesa Laboratories (MLAB) following an internal realignment effective January 12, 2026. This amendment states that certain Vanguard subsidiaries or divisions will now report their beneficial ownership separately. The filing clarifies that while the reporting structure has changed, the underlying investment strategies of these subsidiaries remain the same.
Mesa Laboratories announces CEO transition and board resignation
Mesa Laboratories, Inc. announced the planned departure of President and CEO Gary Owens, effective around April 13, 2026, with Dr. Siddhartha Kadia appointed as his successor. Owens will remain in a non-executive capacity to assist with the transition and will receive severance benefits. The company, which has maintained dividends for 24 years and remains profitable, sees this as a strategic leadership change.
Mesa Laboratories announces CEO transition and board resignation
Mesa Laboratories, Inc. announced the departure of President and CEO Gary Owens, effective April 13, 2026, with Dr. Siddhartha Kadia appointed as his successor. Owens will remain in a non-executive capacity for a transition period and his resignation from the board of directors is not due to any disagreement. The company has maintained dividend payments for 24 years and remains profitable, despite a 34% drop in stock price over the last year.
Mesa Laboratories announces CEO transition and board resignation
Mesa Laboratories, Inc. announced the planned departure of President and CEO Gary Owens, effective around April 13, 2026. Mr. Owens will receive severance and benefits and has resigned from the board. Dr. Siddhartha Kadia has been appointed as the new President and CEO, effective April 13, 2026, and will also join the Board of Directors.
Mesa Laboratories (NASDAQ: MLAB) sets CEO Owens transition and board exit
Mesa Laboratories has detailed the transition plan for President and CEO Gary Owens, whose departure is scheduled for April 13, 2026. Owens will remain in a non-executive role until June 22, 2026, to ensure a smooth handover and will receive severance benefits aligned with a "without cause" termination, including a pro-rated performance stock unit award, contingent on signing a release of claims. He also resigned from the board on March 20, 2026, a move the company states was not due to any disagreements.
Mesa Laboratories, Inc. $MLAB Shares Bought by Crawford Investment Counsel Inc.
Crawford Investment Counsel Inc. significantly increased its stake in Mesa Laboratories (NASDAQ:MLAB) by 59.4% during the third quarter, now owning 82,467 shares valued at $5.53 million. Several other institutional investors also bought shares, with 90.60% of the stock owned by institutions and hedge funds. The article also details recent analyst ratings, financial performance, and insider buying activity, including purchases by directors R Tony Tripeny and Shiraz Shabanali Ladiwala.
Simcoe Capital Management LLC Makes New Investment in Mesa Laboratories, Inc. $MLAB
Simcoe Capital Management LLC has made a new investment in Mesa Laboratories, Inc. (NASDAQ:MLAB), purchasing over 190,000 shares valued at approximately $12.79 million, making it their 14th-largest holding. This investment comes as Mesa Laboratories recently surpassed quarterly earnings expectations. Insider activity also shows directors increasing their stakes in the company, despite a high valuation and a 100% dividend payout ratio.
Long Path (MLAB) reports 311,703 shares, 5.6% ownership stake
Long Path Smaller Companies Fund, LP, along with affiliated entities and co-portfolio managers, has reported a beneficial ownership of 311,703 shares in Mesa Laboratories, Inc. (MLAB), constituting a 5.6% stake. This disclosure was made in a Schedule 13G filing with the SEC, indicating a passive investment. The percentage is based on 5,524,813 outstanding shares as of January 31, 2026.
Gabelli Funds LLC Grows Stake in Mesa Laboratories, Inc. $MLAB
Gabelli Funds LLC significantly increased its stake in Mesa Laboratories, Inc. (MLAB) by 114.6%, bringing their total holdings to 53,974 shares. Despite the company beating quarterly estimates with EPS of $3.07 and revenues of $65.13 million, the stock has recently decreased by 16.5%. Insiders have also been acquiring shares, and the company declared a $0.16 quarterly dividend.
[Form 4] MESA LABORATORIES INC /CO/ Insider Trading Activity
Mesa Laboratories director Shiraz Shabanali Ladiwala reported an open-market purchase of 3,500 shares of Mesa Laboratories common stock at $72.23 per share on March 10, 2026. This transaction increased his direct holdings to 8,523 shares, indicating a larger personal investment in the company. The SEC Form 4 filing details this acquisition, categorized as a positive insider trading event.
Mark Christopher Capone Acquires 1,301 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock
Mesa Laboratories (NASDAQ:MLAB) Director Mark Christopher Capone recently acquired 1,301 shares of the company's stock for a total of $99,331.35, increasing his stake by over 61%. This insider buying occurred as the stock experienced a 16.5% drop despite the company reporting better-than-expected quarterly earnings. The article also highlights analyst ratings, institutional investments, and the company's dividend payout.
Capone Mark Christopher buys Mesa Laboratories shares for $99,331
Director Capone Mark Christopher purchased 1,301 shares of Mesa Laboratories (NASDAQ:MLAB) for $99,331 on March 10, 2026, as per an SEC filing. This insider buying occurred after the stock experienced a nearly 20% drop, with shares trading at $73.47. The company recently announced a leadership change, with Dr. Siddhartha Kadia replacing Gary Owens as President and CEO.
Insider Buying: Mark Capone Acquires Shares of Mesa Laboratories Inc (MLAB)
Mark Capone, a Director at Mesa Laboratories Inc (MLAB), recently purchased 1,301 shares, increasing his total ownership to 3,429 shares. The acquisition occurred when shares were trading at $76.35, valuing the company at a market cap of $404.580 million. According to GuruFocus's GF Value, the stock is considered a "Possible Value Trap, Think Twice," with a price-to-GF-Value ratio of 0.64.
Insider Buying: Mesa Laboratories (NASDAQ:MLAB) Director Buys 3,500 Shares of Stock
Mesa Laboratories (NASDAQ:MLAB) Director Shiraz Shabanali Ladiwala recently purchased 3,500 shares of the company's stock for approximately $252,805, increasing his total holdings by nearly 70%. This insider buying occurred as MLAB shares experienced a notable decline, despite the company reporting better-than-expected earnings and maintaining a quarterly dividend. Analyst ratings for Mesa Laboratories are mixed, with a consensus of "Reduce" and a target price of $94.00.
Mesa Laboratories names new CEO
This article announces that Mesa Laboratories has appointed a new CEO. No further details about the new CEO or the company's future direction are provided in the current content.
Mesa Laboratories Names New CEO for Next Phase
Mesa Laboratories announced that CEO Gary Owens will step down on April 12, 2026, after leading the company since 2017. Dr. Siddhartha Kadia has been appointed as the new President, CEO, and director, effective April 13, 2026, with a compensation package designed to drive the company's next phase of growth. Spark’s AI Analyst rates MLAB stock as Neutral, citing strong cash generation but unstable net earnings and mixed technical momentum.
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Mesa Laboratories, Inc. announced that Gary Owens will step down as President and CEO on April 12, 2026. Dr. Siddhartha Kadia has been appointed as the new President and Chief Executive Officer, effective April 13, 2026, and will also join the Board of Directors. Dr. Kadia brings extensive experience in scaling life sciences businesses, having previously led Calibre Scientific and PhenomeX.
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Mesa Laboratories, Inc. announced that Gary Owens will step down as President and CEO on April 12, 2026, after leading significant growth and expansion for the company since 2017. Dr. Siddhartha Kadia has been appointed as the new President and CEO, effective April 13, 2026, and will also join the Board. Dr. Kadia brings extensive experience in scaling life sciences businesses and commercializing innovative technologies.
